About Zynerba Pharma
Zynerba Pharma is a Healthcare company based in Devon (United States) founded in 2007, and was acquired by Harmony Biosciences in August 2023. Transdermal cannabinoid therapies are developed for neurological disorders. It operates in the Healthcare and Technology sectors. Zynerba Pharma has raised $13 million across 6 funding rounds from investors including Harmony Biosciences, NIH and HHS. The company has 27 employees. Its chief executive, as recorded, is Jeffrey M Dayno. Zynerba Pharma offers products and services including Zygel TM. Its focus areas include High Tech, Nanotechnology, Nanoenabled Products and Life Science. Its legal entity is ZYNERBA PHARMACEUTICALS, INC. Its competitors include Biogen, Neurocrine and PTC Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Zynerba Pharmaceuticals (formerly known as AllTranz) is focused on developing synthetic cannabinoid therapeutics for transdermal delivery. Using its proprietary transdermal technologies, it has developed a controlled delivery of therapeutic levels of two cannabinoids cannabidiol (CBD) and Tetrahydrocannabinol (THC). Its lead candidate ZYN002, a CBD gel, is being studied in refractory epilepsy, FXS, and osteoarthritis. It is also developing ZYN001 which uses pro-drug of THC in a transdermal patch to deliver THC and is currently being studied in fibromyalgia and peripheral neuropathic pain.
- Headquarters Devon, United States
- Employees 27
- Stage Acquired
- SectorsHealthcareTechnology
- Website zynerba.com
- Social LinkedIn X
- Acquired by Harmony Biosciences (Aug 2023)
- Legal Name Zynerba Pharmaceuticals, Inc.
- Annual Revenue$7.25 K (USD)-97as on Dec 31, 2016
- Total Equity Funding$13M (USD)
in 6 rounds
- InvestorsHarmony Biosciences
& 5 more
- Employee Count27
- Acquired byHarmony Biosciences
(Aug 2023)
Products & Services of Zynerba Pharma
Zynerba Pharma offers a comprehensive portfolio of products and services, including Zygel TM.
Transdermal cannabinoid treatment for neuropsychiatric disorders in rare conditions.
Funding Insights of Zynerba Pharma
Zynerba Pharma has successfully raised a total of $13M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $13M
- Total Rounds 6
- First Round $100,565
(Jun 2007)
- Investors Count 5
All 6 funding rounds of Zynerba Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2022 | Post-IPO | – | – | ||
| Oct 2014 | $13M | Series B | – | Perceptive Advisors | – |
| Nov 2009 | $4M | Grant | – | – | |
| Sep 2009 | $4.01M | Grant | – | – | |
| Jun 2009 | $115,025 | Grant | – | – | |
| Jun 2007 | $100,565 | Grant | – | – | – |
6 investors in total: 6 institutional.
Investors in Zynerba Pharma
Zynerba Pharma has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Harmony Biosciences, NIH and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investments are directed toward North American opportunities. | lpcfunds.com | Chicago, United States | ||
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Scientific research on drug use and addiction is supported. | drugabuse.gov | United States | ||
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Developer of therapeutics for rare neurological diseases | 2017 | harmonybiosciences.com | Plymouth Meeting, United States |
Investor details for Zynerba Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Zynerba Pharma
27 people are tracked at Zynerba Pharma (10 in leadership, 15 in board & advisors, 2 in team); the tracked headcount is 27.
| Name | Role | Group |
|---|---|---|
Jeffrey M Dayno | CEO | Leadership |
Ray Mannion | VP, Manufacturing | Leadership |
Brian Rosenberger | VP, Commercial & Business Development | Leadership |
Terri B. Sebree | President | Leadership |
Terry Hurst | General Manager, Australia | Leadership |
Carol O’Neill | VP, Development | Leadership |
Nancy Tich | VP, Clinical | Leadership |
Paul M. Kirsch | Vice President, Regulatory Affairs And Quality Assurance | Leadership |
Stan Banks | Director Of CMC And Product Development | Leadership |
Carolyn Kreusser | Director, Market Insights | Leadership |
Pamela Stephenson | Director | Board & advisors |
Elizabeth M. Berry-Kravis | Scientific Advisor | Board & advisors |
Craig A. Erikson | Scientific Advisor | Board & advisors |
Nicole Tartaglia | Scientific Advisor | Board & advisors |
Warren D. Cooper | Lead Independent Director | Board & advisors |
John P. Butler | Director | Board & advisors |
William J. Federici | Director | Board & advisors |
Daniel L. Kisner | Director | Board & advisors |
Kenneth I. Moch | Director | Board & advisors |
Randi J. Hagerman | Scientific Advisor | Board & advisors |
7 more people are available in the full profile.
Complete people profiles for Zynerba Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Zynerba Pharma
5 dated milestones of Zynerba Pharma across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Zynerba Pharma is founded.
- Funding First funding round of $101K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO,.
- Exit Acquired by Harmony Biosciences.
Competitors of Zynerba Pharma
Zynerba Pharma has 3 listed competitors in our database, 3 of them funded. They include Biogen, Neurocrine and PTC Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| neurocrine.com | 1992 | San Diego, United States | $10M | 1,400 | Developer of small molecule therapeutics for endocrine and CNS disorders | |
| ptcbio.com | 1998 | South Plainfield, United States | $248.1M | 995 | Small molecule drugs for rare diseases are developed. |
Detailed competitors of Zynerba Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Cannabis Health Tech Ecosystem
3 companies that operate in the same segment as Zynerba Pharma (Cannabis Health Tech Ecosystem) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Online marketplace platform for cannabis traders | 2015 | New York, New York, United States | USD 195.4 M | |||
Loyalty and marketing solutions for cannabis dispensaries are provided. | 2012 | West Palm Beach, Florida, United States | USD 25.79 M | USD 22.83 M | ||
An online marketplace for cannabis products is operated. | 2017 | Bend, Oregon, United States | USD 603 M | 469 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Zynerba Pharma
Complete news archive for Zynerba Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Zynerba Pharma
Zynerba Pharma was founded in 2007.
Zynerba Pharma is headquartered in Devon, United States. It is registered at Devon, Pennsylvania, United States.
Jeffrey M Dayno is the CEO of Zynerba Pharma, as recorded in our data.
Zynerba Pharma is a funded company, having raised a total of $13M across 6 funding rounds to date. The company's 1st funding round was a Grant of $100.57K, raised on Jun 2007.
Zynerba Pharma has 27 employees.
Annual revenue of Zynerba Pharma is $7.25K as on Dec 31, 2016.
Zynerba Pharmaceuticals (formerly known as AllTranz) is focused on developing synthetic cannabinoid therapeutics for transdermal delivery. Using its proprietary transdermal technologies, it has developed a controlled delivery of therapeutic levels of two cannabinoids cannabidiol (CBD) and Tetrahydrocannabinol (THC). Its lead candidate ZYN002, a CBD gel, is being studied in refractory epilepsy, FXS, and osteoarthritis. It is also developing ZYN001 which uses pro-drug of THC in a transdermal patch to deliver THC and is currently being studied in fibromyalgia and peripheral neuropathic pain.
Zynerba Pharma's top competitors include PTC Therapeutics, Neurocrine and Biogen.
Zynerba Pharma offers Zygel TM.
Zynerba Pharma has 6 investors. Key investors include Harmony Biosciences, NIH, HHS, Perceptive Advisors, and Lincoln Park Capital.
Zynerba Pharma operates through Zynerba Pharmaceuticals, Inc..
Yes. Zynerba Pharma was acquired by Harmony Biosciences in August 2023.